NCT02752919已完成1 期
A Single Dose Study to Evaluate the Exposure-Response Relationship Between Galunisertib (LY2157299) and QT Interval in Healthy Japanese and Non-Japanese Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Estimated Change from Baseline in Fridericia-corrected QT Interval (QTcF) by Specific Galunisertib Concentrations
研究概览
简要总结
The study involves a single dose of galunisertib taken by mouth by Japanese participants and non-Japanese participants. The study will evaluate the relationship between the effect of the study drug on the electrical activity of the heart, as measured by electrocardiogram (ECG) and how much of the study drug gets into the blood stream and how long it takes the body to remove it. Ths study will last about 42 days for each participant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Are overtly healthy male or female Japanese or non-Japanese participants, as determined by medical history and physical examination.
- •Male participants: Must agree to use a reliable method of birth control for 12 weeks after receiving the dose of study drug, OR be at least 6 weeks post-vasectomy with documentation of sperm-free ejaculate.
- •Female participants: Women not of child-bearing potential may participate, and include those who are:
- •Infertile due to surgical sterilization; or
- •Postmenopausal.
- •All female participants must test negative for pregnancy at screening.
- •Have a body mass index (BMI) of 18.5 to 32.0 kilogram per meter square (kg/m²), inclusive at screening.
- •Have clinical laboratory test results within normal reference range.
- •Are able and willing to give signed informed consent.
排除标准
- •Have participated, within the last 3 months, in a clinical trial involving an Investigational Product (IP). If the previous IP has a long half-life, 3 months should have passed.
- •Have known allergies to galunisertib-related compounds or any components of the formulation, or history of significant atopy.
- •Have a personal or family history of long QT syndrome, heart failure, hypokalemia, or sudden death.
- •Have a personal history of unexplained syncope within the last year.
- •Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study or affects or confounds the corrected QT (QTc) analysis (the ECG waveform morphology or rhythm are incompatible with reliable measurement of ECG intervals), or have QTcF greater than (>) 450 milliseconds (msec).
- •Have an abnormal blood pressure as determined by the investigator.
- •Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the IP; or of interfering with the interpretation of data.
- •Have serum magnesium and potassium values outside of the normal reference range.
- •Show evidence of human immunodeficiency virus (HIV) infection, hepatitis C or hepatitis B.
- •Intend to use over-the-counter or prescription medication (including herbal medications) within 14 days prior to dosing.
- •Have donated blood of more than 500 milliliter (mL) within the last month
- •Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females).
研究组 & 干预措施
Part A Galunisertib - 1 tablet
Experimental
Single oral dose of galunisertib in Japanese participants
干预措施: Galunisertib (Drug)
Part A Galunisertib - 2 tablets
Experimental
Single oral dose of galunisertib in Japanese participants
干预措施: Galunisertib (Drug)
Part B Galunisertib - 1 tablet
Experimental
Single oral dose of galunisertib in non-Japanese participants
干预措施: Galunisertib (Drug)
Part B Galunisertib - 2 tablets
Experimental
Single oral dose of galunisertib in non-Japanese participants
干预措施: Galunisertib (Drug)
结局指标
主要结局
Estimated Change from Baseline in Fridericia-corrected QT Interval (QTcF) by Specific Galunisertib Concentrations
时间窗: Baseline through 72 hours after administration of study drug
次要结局
- Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Galunisertib(Predose through 72 hours after administration of study drug)
- Pharmacokinetics: Time of Cmax (tmax) of Galunisertib(Predose through 72 hours after administration of study drug)
- Pharmacokinetics: Maximum Drug Concentration (Cmax) of Galunisertib(Predose through 72 hours after administration of study drug)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein CholesterolHyperlipidemiaNCT01426412Eli Lilly and Company69
已完成
3 期
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 DiabetesGlucose Metabolism DisordersMetabolic DiseaseEndocrine System DiseasesHypoglycemic AgentsType 2 Diabetes Mellitus (T2DM)Diabetes MellitusDiabetes Mellitus, Type 2NCT04809220Eli Lilly and Company591
已完成
1 期
Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male SubjectsHealthy VolunteersNCT04079062Ono Pharmaceutical Co. Ltd78
已完成
2 期
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic MigraineMigraineNCT02959177Eli Lilly and Company459
已完成
1 期
Japanese phase1 Study of Belimumab (IV vs SC)Systemic Lupus ErythematosusNCT01516450GlaxoSmithKline16